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Abstract: 
Background: High-mobility group A1 (HMGA1) polymorphism has been suspected as a gene variant associated with type 2 
diabetes (T2D). However, conflicting outcomes have been reported. 
Objective: This meta-analysis aimed to predict the association between the HMGA1 variant IVS5-13insC and T2D. 
Methods: Statistical analyses were performed using Stata/SE 12.0 software. 
Results: A total of  11 case-control studies in 6 articles were included. Results suggested that the HMGA1 variant IVS5-13insC 
was associated with an increased risk of  insulin resistance (OR = 0.61, 95% CI 0.56 to 0.66, P < 0.0001), T2D (OR = 0.67, 95% 
CI 0.61 to 0.73, P < 0.0001), particularly for Caucasians with increased risks of  T2D (OR = 0.56, 95% CI 0.49 to 0.65, P < 
0.0001) compared with wild-type subjects. 
Conclusion: This meta-analysis indicated that the HMGA1 variant IVS5-13insC can be a risk factor of  T2D development, 
particularly among Caucasians. Significant risks were also found (Asian: OR = 0.74, 95% CI: 0.63 to 0.86, P < 0.0001, Hispan-
ic-American: OR = 0.81, 95% CI: 0.65 to 1.01, P < 0.0001) in non-Caucasian population. However, ethnical studies should be 
conducted to reveal whether the HMGA1 variant IVS5-13insC is associated with an increased risk of  T2D.
Keywords: HMGA1, type 2 diabetes, insulin resistance, variant, meta-analysis.
DOI: https://dx.doi.org/10.4314/ahs.v18i4.4
Cite as: Liu Y, Zheng L, Kong H, Wang Q, Tian X. HMGA1 variant IVS5-13insC is associated with insulin resistance and type 2 diabetes: 
an updated meta-analysis. Afri Health Sci. 2018;18(4): 865-872. https://dx.doi.org/10.4314/ahs.v18i4.4
Corresponding author:
Qinglu Wang,
Key Laboratory of  Biomedical Engineering 
& Technology 
of  Shandong High School, 
Qilu Medical University, Zibo, 255213, China.
Email: wql_zcq@126.com
Introduction
Type 2 diabetes (T2D) is one of  the major and exacer-
bating health problems worldwide; T2D is predicted to 
affect 490 million in 20301. Strong genetic influences and 
many polymorphisms have been reproducibly associated 
with T2D2,3. Insulin resistance in muscle, liver, and adi-
pose tissues is a primary characteristic of  most patients 
with T2D; as such, these tissues become resistant to en-
dogenous and exogenous insulin. The interaction of  in-
sulin with target tissues is mediated by insulin receptor 
(INSR), a glycoprotein implicated in directing insulin to 
target cells and initiating cell responses to insulin4.
High-mobility group A1 (HMGA1) is an architectur-
al transcription factor involved in numerous biological 
functions in the nucleus, including regulation of  DNA 
replication, transcription, recombination, and repair; 
among these functions, transcriptional regulation of  
gene expression is considered as the most important. 
After HMGA1 binds to DNA, HMGA1 can be polym-
erized with other transcription factors, forming an “en-
African Health Sciences Vol 18 Issue 4, December, 2018
© 2018 Liu et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of  the Creative commons Attribution 
License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 




hanceosome” to regulate gene transcription; thus, gene 
expressions are positively or negatively regulated5. Stud-
ies on humans and knockout mice have suggested that 
HMGA1 is involved in T2D pathogenesis through the 
regulation of  INSR gene expression; INSR gene expres-
sion is decreased by functional HMGA1 gene variants6. 
HMGA1-deficient patients have been biologically inves-
tigated because of  their clinical value. However, whether 
HMGA1 single gene deletion- or mutation-induced in-
sulin resistance is the underlying cause of  T2D remains 
unknown.
Low-frequency insertion polymorphism IVS5-13insC 
(c.136-14_136-13insC) has been identified and associ-
ated with insulin resistance and T2D among individuals 
of  white European ancestry and Chinese populations7,8. 
However, no similar association is observed in another 
study involving Caucasians and populations of  African 
and Hispanic descent9,10,11. Furthermore, conflicting re-
sults regarding the association of  HMGA1 with T2D and 
insufficient data on diverse ethnic groups have caused 
difficulty in performing clinical translation of  HMGA1 
IVS5-13insC genotyping.
Results regarding the functional effect of  the HMGA1 
IVS5-13insC variant are also contradictory. On one hand, 
HMGA1 and INSR expressions decrease in diabetic car-
riers of  IVS5-13insC compared with those of  wild-type 
diabetic and non-diabetic patients8. INSR protein ex-
pression and insulin-binding capacity are also restored in 
lymphoblasts obtained from diabetic IVS5-13insC carri-
ers through HMGA1 DNA transfection. On the other 
hand, IVS5-13insC does not affect HMGA1 or INSR ex-
pression in adipose tissues of  normoglycemic patients11. 
IVS5-13insC is present at position 13 of  HMGA1 exon 
6; however, the direct mechanism by which this variant 
affects mRNA expression or amino acid sequence re-
mains unclear.
A previous meta-analysis of  Caucasians focused on this 
issue and arrived at a negative conclusion11. Thus, we per-
formed a meta-analysis of  eligible case-control studies 
worldwide to investigate whether the HMGA1 variant 
IVS5-13insC is associated with an increased risk of  in-
sulin resistance and T2D. We also conducted sub-group 
analyses according to different ethnicities to explore the 
presence of  ethnicity-specific effects.
Materials and methods
Literature search strategy
We searched Pubmed, EMBASE, and Web of  science. 
The last updated search was performed on June 30, 2017. 
We used any possible combinations of  relevant keywords: 
“HMGA1 or high-mobility group A1,” “polymorphism 
or mutation or mutant or variant,” and “insulin resistance, 
T2D, or type 2 diabetes.”
Articles describing the relationship between T2D and 
IVS5-13insC were identified with only published studies 
in English. The inclusion criteria were set as follows: (a) 
evaluation of  IVS5-13insC, insulin resistance, and T2D 
risk and (b) case-control design to estimate odds ratio 
(OR) with a 95% confidence interval (CI). Articles were 
excluded according to the following criteria: (a) reviews, 
meta-analyses, and other non-case-control studies and (b) 
non-human studies. For studies with the same or over-
lapping data by the same authors, the most suitable stud-
ies with the largest number of  cases or latest publication 
dates were selected. The searching was also supplement-
ed by retrieving additional studies from selected article’s 
references and citations and from the pubmed option re-
lated articles.
Data extraction
Two reviewers (Yancheng Liu and Liting Zheng) inde-
pendently extracted information from all of  the eligible 
publications and reached consensus on all items. A third 
author (Hao Kong) was invited to assess articles in case 
of  disagreement. The following information was extract-
ed from each article: first author, journal, year of  publica-
tion, country of  origin, ethnicity, and exact data of  cases 
and controls.
Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess 
the methodological quality of  included studies. As quite 
comprehensive and partly validated, the NOS, a star-
based system allowing a semi-quantitative assessment of  
non-randomized study quality, consists of  eight items 
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and takes into consideration three major parameters, in-
cluding selection of  participants, comparability of  study 
groups, and exposure. The scale ranges from 0 to 9stars, 
with more stars indicating a higher quality study12.
Statistical analysis
The T2D risk associated with IVS5-13insC was evaluated 
using ORs with a 95% CI. Heterogeneity (I2) was evalu-
ated using a Cochran’s Q statistic to assess the degree of  
inter-study variation. The pooled OR of  each study was 
calculated using a fixed-effects model when no statistical-
ly significant heterogeneity was detected with a P value < 
0.10. A random-effects model was used when significant 
heterogeneity was found.
The statistical significance of  the pooled ORs was de-
termined using a Z test. P value < 0.05 was considered 
significant. A stratified analysis of  ethnicity and continent 
was also performed: (1) Caucasian and non-Caucasian and 
(2) Asian and European. Egger’s plot was used to evalu-
ate the probability of  publication bias. Statistical analyses 
were carried out using Stata/SE 12.0 for Windows.
Results
Characteristics of  the studies
Figure 1 demonstrates the progress of  the article selec-
tion. After initially searching PubMed, EMBASE, and 
Web of  science, we identified 52 publications. Of  these 
52 publications, 34 were excluded after titles and abstracts 
were scanned to determine whether or not these articles 
are relevant to T2D and HMGA1 polymorphism; as a 
result, 18 articles were considered for further assessment. 
Of  these 18 articles, 11 were not related to the HMGA1 
variant IVS5-13insC; thus, these articles were removed 
from the list. After reading the full text of  the 7 remain-
ing studies, we excluded 1 article that did not compare 
between T2D patients and healthy controls. As a result, 
11 case-control studies from 6 articles (5 articles about 
T2D7,8,9,10,11 and 1 article about MetS13) were includ-
ed in our meta-analysis. Selected studies were primarily 
conducted in Europe, Asia, and South America. Reports 
from other areas were limited. We estimated the risk be-
tween T2D and control groups by comparing gene fre-
quencies of  the HMGA1 variant IVS5-13insC (del/ins, 
ins/ins) and the wild type (del/del).  
 
Fig. 1 Flow diagram of included/excluded studies 
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According to the NOS, overall quality ratings of  the stud-
ies ranged from 5 to 8, with a median NOS score of  7. A 
dominant genetic model was adopted on the basis of  pre-
vious observations indicating that: no statistical difference 
in results was observed between dominant and additive 
models. We preferentially used adjusted ORs reported by 
the authors. If  no adjusted estimates were presented, we 
included the crude estimate. The pooled-effects estimates 
were used to combine values from the single studies and 
were expressed as OR and the related 95% CI. The de-
tailed information of  each study is shown in Table 1.
Table 1 Characteristics of the11 case-controls included in the meta-analysis 
First author 
(years) 
Disease Country Ethnicity Non-diabetic patients genotype Diabetic patients genotype Model Adjusted RR/OR 




(c/c or c/-) 
Wild type (-/-) Mutant type (c/c 
or c/-) 





293 531 135 185 Dominant model 1.44(1.09-1.90) 7 





45 597 69 868 Dominant model 0.79(0.49-1.25) 5 
African-
American 
6 147 6 210 Dominant model 1.51(0.48-4.74) 5 
Caucasian 18 475 17 591 Dominant model 0.95(0.44-2.06) 5 
Chiefari 
(2013) 
MetS Italian Caucasian 195 4821 299 3106 Dominant model 2.42(2.00-2.92) 8 
Chiefari 
(2013) 
MetS Turkish Caucasian 57 703 72 587 Dominant model 1.66(1.15-2.39) 8 
Liu (2012) T2D China Asian 354 2358 436 2139 Dominant model 1.34(1.15-1.56) 8 
                Additive model 1.34(1.16-1.55) - 
Marquez 
(2012) 
T2D France Caucasian 228 4159 267 4639 Dominant model 1.07(0.84-1.37) 7 
Chiefari 
(2011) 
T2D Italy Caucasian 11 2533 237 3041 Dominant model 15.7(8.57-29.03) 8 
Chiefari 
(2011) 
T2D America Caucasian 45 913 75 895 Dominant model 1.64(1.05-2.57) 8 
Chiefari 
(2011) 
T2D France Caucasian 0 50 27 327 Dominant model - 8 
MetS: The metabolic syndrome is a common multicomponent disorder where insulin resistance is associated with an increased risk for type 2 diabetes (T2D), hypertension, dyslipidemia, and cardiovascular  
disease (CVD). 
  
Overall meta-analysis and sub-group analysis
A summary of  the meta-analysis of  the HMGA1 vari-
ant IVS5-13insC and T2D is shown in Figure 2. The 
HMGA1 variant IVS5-13insC was significantly associat-
ed with an increased risk of  insulin resistance and T2D 
compared with that of  healthy controls in overall pop-
ulations (insulin resistance: OR = 0.61, 95% CI 0.56 to 
0.66, P < 0.0001; T2D: OR = 0.67, 95% CI 0.61 to 0.73, 
P < 0.0001), and high heterogeneity (insulin resistance: 
I2=91.3%; T2D: I2= 91.7%).
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Fig. 2 Meta-analysis of the HMGA1 variant IVS5-13insC and T2D 
Sub-group analysis was performed according to different 
ethnic groups in this meta-analysis. Significant associa-
tions were found in Figure 3 (OR = 0.56, 95% CI: 0.49 to 
0.65, P < 0.0001) in the Caucasian population; an increas-
ing pattern was observed in non-Caucasian populations 
(Asian: OR = 0.74, 95% CI: 0.63 to 0.86, P < 0.0001, 
Hispanic-American: OR = 0.81, 95% CI: 0.65 to 1.01, P 
< 0.0001).
  
   
Fig.3 Subgroup meta-analysis of different ethnic groups 
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Publication bias
Egger’s test revealed a consistent outcome. Egger’s plot 
indicated a lack of  publication bias.
Discussion
This meta-analysis identify the increased T2D vulnerabil-
ity of  the HMGA1 variant IVS5-13insC variant carriers; 
our results suggested that the HMGA1 variant IVS5-13in-
sC variant is likely involved in T2D pathogenesis. How-
ever, a previous meta-analysis of  Caucasians revealed that 
the HMGA1 variant IVS5-13insC is not associated with 
T2D11. Recently, a meta-analysis of  Caucasians and other 
populations showed that the HMGA1 variant IVS5-13in-
sC may increase the prevalence of  T2D14. Compared with 
this meta-analysis, our meta-analysis added two sets of  
data from an article about MetS in order to analyze the 
association between the HMGA1 variant and insulin re-
sistance. Our meta-analysis showed the same conclusion 
that the HMGA1 variant IVS5-13insC may increase insu-
lin resistance and the prevalence of  T2D. Furthermore, 
the HMGA1 variant IVS5-13insC may increase the prev-
alence of  T2D in other ethnic groups.
Genome-wide association studies (GWAS) on patients 
with T2D have identified associations between polymor-
phisms and mutations in some genes15. These genes have 
been regarded as potential T2D risk factors. However, 
current GWAS failed to detect an association between the 
HMGA1 variant IVS5-13insC and the presence of  T2D. 
To the best of  our knowledge, future meta-analyses that 
include GWAS datasets will help determine whether the 
IVS5-13insC shows a consistent association with T2D.
The limitations of  our study are as follows. First, only 
published studies in English were included in our data 
analysis; other languages or unpublished materials could 
have been overlooked. Second, majority of  the studies 
involved Caucasian populations, whereas four studies fo-
cused on non-Caucasian populations. Thus, further stud-
ies on other populations should be conducted to investi-
gate such association among non-Caucasian populations. 
Third, the ORs obtained using comparison models were 
unadjusted; a precise analysis should be conducted if  in-
dividual raw data were available. Finally, two meta-anal-
yses indicated significant heterogeneity. Despite these 
restrictions, our study provided a comprehensive under-
standing of  the association between the HMGA1 variant 
IVS5-13insC and risk of  T2D.
Conclusion  
The HMGA1 variant IVS5-13insC can be regarded as a 
new risk factor of  the development of  insulin resistance 
and T2D, particularly among Caucasians. Furthermore, 
Asian and Hispanic-American ethnic groups fail to indi-
cate ethnic diversity of  disease susceptibility. In the fu-
ture, case-control investigations of  many ethnic groups 
and communities should be performed to reveal whether 
the HMGA1 variant IVS5-13insC is associated with an 
increased risk of  T2D and to determine ethnicity-specific 
effects.
HMGAl plays a crucial role in blood sugar balance as a 
structural transcription factor. We believe that an indi-
vidual with the HMGA1 variant IVS5-13insC has clini-
cal implications. First, the presence of  these variants can 
serve as an early predictive marker of  both insulin resis-
tance and T2D, especially for individuals with family his-
tories of  T2D and related conditions. Second, the pres-
ence of  these variants may predict responses to therapy16. 
T2D treatment is largely empirical and the prediction of  
specific responses to a therapeutic agent in any patient is 
difficult10. Patients with T2D and variants may respond 
differently to specific therapies, such as an insulin sen-
sitizer, because HMGA1 variant IVS5-13insC defines a 
specific defect that decreases insulin receptor concentra-
tions and insulin resistance. Third, individuals possessing 
functional HMGA1 variant IVS5-13insC and T2D may 
have different clinical courses from other patients with 
T2D, including differences in the development of  com-
plications. Fourth, the search for new therapies for T2D 
can include agents that upregulate HMGA1 expression. 
Finally, this conclusion provides some theoretical basis 
for HMGA1 single gene deletion- or mutation-induced 
insulin resistance as the underlying cause of  T2D. Fur-
thermore, IVS5-13insC can be regarded as a novel target 
of  gene therapy for T2D and insulin resistance.
The exact biological mechanism underlying the associa-
tion between the HMGA1 gene and risk of  T2D remains 
uncertain. Functional studies and succeeding replications 
of  these associations are necessary to define the potential 
role of  the HMGA1 variant IVS5-13insC in predicting 
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T2D developments. Although the current study provides 
this conclusion, further studies on HMGA1 are warrant-
ed to clarify the role of  this gene in diabetes pathogenesis.
HMGA1 has been extensively investigated. A study 
demonstrate that a relationship exists between the 
HMGA1 IVS5-13insC and AMI, suggesting that defects 
at the HMGA1 may play a pathogenetic role in AMI, in 
the absence of  T2D and other cardiovascular risk fac-
tors17. Besides, HMGA1 is highly expressed in tumor 
cells; furthermore, HMGA1 is implicated in tumor ini-
tiation and progression by disrupting the stability of  mi-
tochondrial genome or by participating in the transcrip-
tional regulation of  gene expression related to tumors18. 
Thus, accurate physiological characteristics of  HMGA1 
polymorphism should be determined through several ap-
proaches.
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